MAPT and Alzheimer disease: Of note, the therapeutic formulation tested contained diverse agents associated with various AD-relevant effects such as the reduction of Aβ generation, tau phosphorylation, γ-secretase activity and presenilin-1 expression, as well as the ability to compensate for APOE deficiency by increasing levels of ATP, acetylcholine and glutathione.